Biliary Atresia

Biliary Atresia - Bile Duct Blues

• Progressive, idiopathic, fibro-obliterative disease of neonatal intrahepatic and/or extrahepatic bile ducts, leading to biliary obstruction.
• Incidence: 1 in 10,000-15,000 live births; more common in East Asia.

• Types (Kasai Classification):
  • Type I (~5%): Atresia of common bile duct (CBD); patent proximal ducts.
  • Type II (~2%): Atresia of common hepatic duct (CHD).
    • IIa: Cystic duct joins patent CHD.
    • IIb: Cystic duct joins patent CBD.
  • Type III (>90%): Atresia at porta hepatis (most common); no correctable extrahepatic ducts.
• Etiology (multifactorial, exact cause unknown):
  • Viral infections (Reovirus 3, CMV).
  • Immune-mediated inflammation (e.g., ↑Th1 response).
  • Genetic predisposition (e.g., CFC1, ADD3 genes).
  • Developmental malformation (e.g., Biliary Atresia Splenic Malformation [BASM] syndrome).

⭐ Type III biliary atresia is the most frequent, accounting for over 90% of cases, and involves atresia of ducts at the porta hepatis.

Biliary Atresia - Jaundice Jigsaw

• Patho: Progressive fibro-obliteration of extrahepatic biliary ducts. Most common: Type III (atresia at porta hepatis, ~90%).
• Classic Triad: Jaundice (conjugated, persistent >2 wks), acholic stools, dark urine.
• Signs: Firm hepatomegaly, failure to thrive (late).
• Labs: ↑ Direct bilirubin, ↑ GGT (key marker), ↑ ALP.

⭐ Kasai portoenterostomy performed before 60 days of life offers the best chance of establishing bile flow and native liver survival.

• Management:
  • Kasai (hepatoportoenterostomy): Aim <60-90 days.
  • Liver Transplant: If Kasai fails or late diagnosis.
  • Supportive: Fat-soluble vitamins (A,D,E,K), UDCA.
• Prognosis: Guarded. 5-year native liver survival post-Kasai: 30-60%.
• Complications: Cholangitis (recurrent), portal HTN, cirrhosis, hepatopulmonary syndrome.

Biliary Atresia - Kasai & Beyond

• Kasai Portoenterostomy (Hepatoportoenterostomy):
  • Surgical treatment of choice.
  • Anastomosis of a Roux-en-Y loop of jejunum to the porta hepatis.
  • Goal: Achieve bile drainage.
  • 
• Optimal Timing for Kasai:
  • Crucial for success: < 60-90 days of life.
  • Best outcomes if performed < 45 days.
  • Delayed surgery → progressive fibrosis, ↓ poorer prognosis.
• Post-Kasai Management:
  • Ursodeoxycholic acid (UDCA) to promote bile flow.
  • Fat-soluble vitamins (A, D, E, K) supplementation.
  • Prophylactic antibiotics to prevent cholangitis.
  • Nutritional support for growth.
• Complications Post-Kasai:
  • Recurrent cholangitis (most common).
  • Portal hypertension (e.g., varices, ascites).
  • Progressive liver fibrosis/cirrhosis.
  • Failure to drain bile / Kasai failure.
• Prognosis & Liver Transplantation (LTx):
  • Native liver survival: ~30-50% at 5 years post-Kasai.
  • Many require LTx by adulthood.
  • LTx is definitive for failed Kasai or end-stage liver disease complications.

  ⭐ Majority of patients with biliary atresia will eventually require liver transplantation, even with an initially successful Kasai procedure.

High‑Yield Points - ⚡ Biggest Takeaways

• Biliary Atresia: Most common surgical cause of neonatal cholestasis; leading indication for pediatric liver transplant.
• Presents with persistent jaundice (>2 weeks), acholic stools, dark urine, and conjugated hyperbilirubinemia.
• Kasai portoenterostomy is the initial palliative surgery.
• Optimal Kasai timing: Before 60-90 days of age for better prognosis.
• Many patients ultimately require liver transplantation despite Kasai.
• Intraoperative cholangiogram is diagnostic; triangular cord sign on US is suggestive.